DUBLIN, Calif., and JENA, Germany—Carl Zeiss Meditec, which in August consolidated its ophthalmic diagnostic and surgical business into a single business unit (global ophthalmic devices), has named Andrew Ihan Chang to lead the global sales organization for this newly consolidated group. This business unit is comprised of surgical ophthalmology, ophthalmic diagnostics and refractive lasers.

Chang previously was general manager and senior vice president for Bausch + Lomb Surgical, where he led sales, marketing, operations and business development for the U.S. market.

“Andy Chang’s appointment is the next crucial step in strengthening Zeiss’ commitment to our customers,” said Jim Mazzo, who was named as global president ophthalmic devices of Carl Zeiss Meditec at the time of the August consolidation.

“Andy joins Zeiss at a pivotal time with the consolidation of our ophthalmic business worldwide. His appointment underscores our mission to collaborate more closely with doctors to provide unique innovations and technology solutions to increase efficiency in their daily practice and deliver the best patient care.”

Mazzo noted that Chang has a breadth of experience across the ophthalmic industry in diagnostic and surgical devices, as well as pharmaceuticals. “He has exceptional understanding of what ophthalmologists and optometrists need to achieve and the challenges they face in daily practice,” Mazzo added.

“Andy’s customer-focused leadership and philosophy of partnership, collaboration and cross-over integration with clinicians supports expanding our offerings to our ophthalmic and optometric customers worldwide,” he said.

Before his key roles at Bausch + Lomb Surgical, Chang led the marketing and launch of new laser systems and new indications globally at Optimedica/Abbott Medical Optics. He also held various marketing, sales and product development roles and led the market introductions of ophthalmic pharmaceuticals while working at ISTA Pharmaceutical/Bausch + Lomb earlier in his career.